#1Harnessing The Power Of The Immune System To Fight Human Diseases August 2022 ‒‒‒‒‒‒‒ BIONTECH#2This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: our expected revenues and net profit related to sales of our COVID-19 vaccine, referred to as COMIRNATY® where approved for use under full or conditional marketing authorization, in territories controlled by our collaboration partners, particularly for those figures that are derived from preliminary estimates provided by our partners; our pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after our initial sales to national governments; the future commercial demand and medical need for initial or booster doses of a COVID- 19 vaccine; competition from other COVID-19 vaccines or related to our other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the rate and degree of market acceptance of our COVID-19 vaccine and, if approved, our investigational medicines; the initiation, timing, progress, results, and cost of our research and development programs, including those relating to additional formulations of our COVID-19 vaccine, and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the timing of and our ability to obtain and maintain regulatory approval for our product candidates; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; our and our counterparties' ability to manage and source necessary energy resources; our ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of our third-party collaborators to continue research and development activities relating to our development candidates and investigational medicines; the impact of the COVID-19 pandemic on our development programs, supply chain, collaborators and financial performance; unforeseen safety issues and claims for personal injury or death arising from the use of our COVID-19 vaccine and other products and product candidates developed or manufactured by us; our ability to progress our Malaria, Tuberculosis and HIV programs, including timing for selecting clinical candidates for these programs and the commencement of a clinical trial, as well as any data readouts; the nature and duration of support from the World Health Organization, the European Commission and other organizations with establishing infrastructure; the development of sustainable vaccine production and supply solutions on the African continent, including our BioNTainers, and the nature and feasibility of these solutions; our estimates of research and development revenues, commercial revenues, cost of sales, research and development expenses, sales and marketing expenses, general and administrative expenses, capital expenditures, income taxes, shares outstanding; our ability and that of our collaborators to commercialize and market our product candidates, if approved, including our COVID-19 vaccine; our ability to manage our development and expansion; regulatory developments in the United States and foreign countries; our ability to effectively scale our production capabilities and manufacture our products, including our target COVID-19 vaccine production levels, and our product candidates; and other factors not known to us at this time. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. You should review the risks and uncertainties described under the heading "Risk Factors" in our quarterly report for the three months ended June 30, 2022 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at https://www.sec.gov/. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech's current expectations and speak only as of the date hereof. 2 BIONTECH#3Safety Information COMIRNATYⓇ (the Pfizer-BioNTech COVID-19 vaccine) has been granted conditional marketing authorization (CMA) by the European Commission to prevent coronavirus disease 2019 (COVID-19) in people from 5 yrs of age. The vaccine is administered as a 2-dose series, 3 weeks apart. In addition, the CMA has been expanded to include a booster dose (third dose) at least 6 months after the second dose in individuals 18 yrs of age and older. For immunocompromised individuals, the third dose may be given at least 28 days after the second dose. The European Medicines Agency's (EMA's) human medicines committee (CHMP) has completed its rigorous evaluation of COMIRNATY®, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are now available. IMPORTANT SAFETY INFORMATION: Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine. Very rare cases of myocarditis and pericarditis have been observed following vaccination with Comirnaty. These cases have primarily occurred within 14 days following vaccination, more often after the second vaccination, and more often in younger men. Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general. Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions (e.g. dizziness, palpitations, increases in heart rate, alterations in blood pressure, tingling sensations and sweating) may occur in association with the vaccination process itself. Stress-related reactions are temporary and resolve on their own. Individuals should be advised to bring symptoms to the attention of the vaccination provider for evaluation. It is important that precautions are in place to avoid injury from fainting. • The efficacy, safety and immunogenicity of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of COMIRNATY® may be lower in immunosuppressed individuals. ● 3 · • As with any vaccine, vaccination with COMIRNATY® may not protect all vaccine recipients. Individuals may not be fully protected until 7 days after their second dose of vaccine. In clinical studies, adverse reactions in participants 16 yrs of age and older were injection site pain (> 80%), fatigue (> 60%), headache (> 50%), myalgia and chills (> 30%), arthralgia (> 20%), pyrexia and injection site swelling (> 10%) and were usually mild or moderate in intensity and resolved within a few days after vaccination. A slightly lower frequency of reactogenicity events was associated with greater age. • The overall safety profile of COMIRNATY® in participants 5 to 15 yrs of age was similar to that seen in participants 16 yrs of age and older. • The most frequent adverse reactions in children 5 to 11 yrs of age were injection site pain (>80%), fatigue (>50%), headache (>30%), injection site redness and swelling (>20%), myalgia and chills (>10%). • The most frequent adverse reactions in clinical trial participants 12 to 15 yrs of age were injection site pain (> 90%), fatigue and headache (> 70%), myalgia and chills (> 40%), arthralgia and pyrexia (> 20%). There is limited experience with use of COMIRNATY® in pregnant women. Administration of COMIRNATY® in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and fetus. It is unknown whether COMIRNATY® is excreted in human milk. ● ● . . · Interactions with other medicinal products or concomitant administration of COMIRNATYⓇ with other vaccines has not been studied. For complete information on the safety of COMIRNATY® always make reference to the approved Summary of Product Characteristics and Package Leaflet available in all the languages of the European Union on the EMA website. The black equilateral triangle ▼ denotes that additional monitoring is required to capture any adverse reactions. This will allow quick identification of new safety information. Individuals can help by reporting any side effects they may get. Side effects can be reported to EudraVigilance or directly to BioNTech using email [email protected], telephone +49 6131 9084 0, or via the website www.biontech.de BIONTECH#4Safety Information AUTHORIZED USE IN THE U.S. COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 yrs of age and older. It is also authorized under EUA to provide a 3-dose primary series to individuals 6 months through 4 yrs of age, 2-dose primary series to individuals 5 yrs of age and older, a third primary series dose to individuals 5 yrs of age and older who have been determined to have certain kinds of immunocompromise, a single booster dose to individuals 5 through 11 yrs of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine or COMIRNATYⓇ, a third primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise, a first booster dose to individuals 12 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY®, a first booster dose to individuals 18 yrs of age and older who have completed primary vaccination with a different authorized COVID-19 vaccine, a second booster dose to individuals 50 yrs of age and older who have received a first booster dose of any authorized COVID-19 vaccine; and a second booster dose to individuals 12 yrs of age and older who have been determined to have certain kinds of immunocompromise and who have received a first booster dose of any authorized COVID-19 vaccine. The booster schedule is based on the labeling information of the vaccine used for the primary series. IMPORTANT SAFETY INFORMATION Individuals should not get the vaccine if they: had a severe allergic reaction after a previous dose of this vaccine • had a severe allergic reaction to any ingredient of this vaccine Individuals should tell the vaccination provider about all of their medical conditions, including if they: have any allergies have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart) • have a fever . 4 ● ● ● ● have a bleeding disorder or are on a blood thinner are immunocompromised or are on a medicine that affects the immune system are pregnant, plan to become pregnant, or are breastfeeding have received another COVID-19 vaccine have ever fainted in association with an injection The vaccine may not protect everyone. Side effects reported with the vaccine include: • There is a remote chance that the vaccine could cause a severe allergic reaction o A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of the vaccine. For this reason, vaccination providers may ask individuals to stay at the place where they received the vaccine for monitoring after vaccination Signs of a severe allergic reaction can include difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness If an individual experiences a severe allergic reaction, they should call 9-1-1 or go to the nearest hospital o O BIONTECH#5Safety Information Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine, more commonly in males under 40 yrs of age than among females and older males. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine: O chest pain O shortness of breath o feelings of having a fast-beating, fluttering, or pounding heart 01 Additional side effects that have been reported with the vaccine include: O severe allergic reactions; non-severe allergic reactions such as injection site pain; tiredness; headache; muscle pain; chills; joint pain; fever; injection site swelling; injection site redness; nausea; feeling unwell; swollen lymph nodes (lymphadenopathy); decreased appetite; diarrhea; vomiting; arm pain; and fainting in association with injection of the vaccine Data on administration of this vaccine at the same time as other vaccines have not yet been submitted to FDA. Individuals considering receiving this vaccine with other vaccines should discuss their options with their healthcare provider. 5 These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The possible side effects of the vaccine are still being studied in clinical trials. Call the vaccination provider or health care provider about bothersome side effects or side effects that do not go away Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit https://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafety reporting. com or by calling 1-800-438-1985. BIONTECH#609 OUR VISION Harnessing the power of the immune system to develop novel therapies. against cancer, infectious diseases and other severe diseases. BIONTECH#7BioNTech Today | A 21st Century Immunotherapy Powerhouse 7 Fully Integrated Biotechnology Company Technology-agnostic Multi-Platform Strategy Our Approach to Global Social Responsibility Focus on high medical needs. Democratize access to novel medicines. 只只只 Diversified Product Pipeline BIONTECH#82021: Key Highlights of Progress Towards Vision 8 COMIRNATY - GLOBAL LEADERSHIP Five randomized phase 2 trials ~2.6 bn doses delivered to in 2021¹ > 165 Countries & territories ¹ DROVE ADVANCEMENT IN ONCOLOGY Four new platforms entered the clinic (FIH) EXPANDED GLOBAL ORGANIZATION 3,000+ team members Increased footprint with new offices in U.S., Europe and Asia >1 bn to low- and middle- income countries ¹ Three strategic M&As to complement existing technologies STRONG FINANCIAL PERFORMANCE €19.0 Bn €39.63 Total 2021 Revenues² Diluted EPS² 1 As of end 2021; 2 Estimated figures based on preliminary data shared between Pfizer and BioNTech as further described in our Annual Report on Form 20-F for the year ending December 31, 2021; FIH: First in humans BIONTECH#92021: A Year of Transformation & Progress 9 H Expansion of oncology pipeline Expansion of R&D and production teams Production capacity Global presence Commercial infrastructure 1 As of December 31, 2021, BioNTech Group; R&D: Research & development Nine oncology clinical trials started; clinical results from six phase 1 studies Increased R&D and production teams to >2,000 professionals ¹ Expansion of commercial scale mRNA production and addition of US cell therapy manufacturing facility Established offices in Singapore, China and Turkey Deployed commercial team in Germany BIONTECH#10Diversity - Important Success Factor Mainz (Hauptsitz) 10 Marburg Idar-Oberstein Berlin Halle Neuried Martinsried Seven sites in Germany 1 As of December 31, 2021, BioNTech Group > 3,000 employees ¹ > 60 nationalities > 1,200 new colleagues Female employees in the total workforce 51% Females in top management positions 43% Cambridge, USA Gaithersburg, USA Istanbul, Turkey Twelve subsidiaries worldwide Singapore Shanghai, China Reading, UK Vienna, Austria BIONTECH#11Global Social Responsibility at Our Core Democratize Access to Novel Medicines 11 COVID-19 vaccine pledge to COVAX and the world 2+ bn doses to low- and middle-income countries by end of 2022 Development of new drugs for diseases with high unmet medical need in low-income countries Malaria Tuberculosis ● HIV Start to establish mRNA production in Africa to ensure local vaccine supply Modular "BioN Tainer" mRNA production facilities as technological solution to democratize access to novel medicines SBTI, Science Based Targets initiative (in line with Paris agreement) 1 base year: 2021; 2 encompasses adhering to ten principles on human rights, the environment and anti-corruption TAIP P Environmental & Climate Protection Climate targets under SBTi Scope 1 & 2: absolute emission reduction of 42% by 20301 Responsible Governance Practice good corporate governance and social and societal responsibility Signed UN Global Compact² ● Attractive Employer Recruitment of qualified employees ● Specialists for scientific innovation and support of global growth BIONTECH#12We Collaborate with Global Leaders in Our Industry COVID-19 Vaccine 50:50 gross profit share¹ 2Pfizer 12 FOSUNPHARMA Fix Vac Melanoma Companies keep full rights to own product Collaborations for clinical stage programs Bispecific mABs 50:50 cost & profit share Genmab REGENERON Shingles Cost and gross profit share 2Pfizer iNeST 50:50 cost & profit share Genentech Pre-clinical collaborations Up to 10 Infectious Disease Indications worldwide opt-in right University of Pennsylvania 150:50 cost & profit share refers to terms of Pfizer collaboration only (world-wide ex-China) HIV, Tuberculosis developed world rights BILL & MELINDA GATES foundation Intra-tumoral mRNA cost & profit share SANOFI Seasonal Influenza royalties & milestones Pfizer 5 Rare Disease Indications 50:50 cost & profit share GENEVANT BIONTECH#13MULTI-PLATFORM STRATEGY BIONTECH#14Multi-platform Strategy: Toolbox for Innovation 14 RIBOLYSINS Precision antibacterials (Phagomed) Internal technology Acquisition Collaboration Digital & Al capabilities INDIVIDUALIZED mRNA CANCER VACCINES iNeST INFECTIOUS DISEASES VACCINES • Prophylactic vaccines • Therapeutic vaccines *mRNA encoded cancer-targeting antibodies and cytokines OFF-THE-SHELF mRNA CANCER VACCINES FixVac mRNA TECHNOLOGY LIPID- NANOCRYSTAL- FORMULATIONS (Matinas) ARTIFICIAL INTELLIGENCE • mRNA Drug Design Early SARS- CoV-2 variant detection RIBO- LOGICALS* RiboCytokines • RiboMabs CARVac mRNA Vaccine boosted CAR-T cells PERSONA- LIZED TCR- THERAPY MULTI-TARGET TCR RESEARCH COLLABORATION (Medigene) CELL & GENE THERAPIES INDIVIDUALIZED NEOANTIGEN T CELL THERAPY mRNA ENCODED HUMABODIES (Crescendo) SOLID TUMOR CAR-T Ideal CAR-T cell targets NEXT GEN IMMUNE CHECKPOINT MODULATORS Bispecific antibodies ANTIBODIES SMALL MOLECULES TARGETED CANCER THERAPIES SELECTIVE TLR-7 ANTAGONISM BIONTECH#15KM DIVERSIFIED PRODUCT PIPELINE#16Advancing Toward Our Vision 1 marketed vaccine Market leader in COVID-19 vaccines 18 programs in 23 clinical trials 5 randomized Phase 2 trials 16 Oncology 1 Phase 1 program 10+ preclinical programs, 4 FIH trials to start Infectious diseases Driving transformation today Next-gen or variant adapted COVID-19 vaccines Multiple product launches in next 3-5 yrs 5-10 IND submissions per year Mid-term goals Once in a generation opportunity to transform medicine Maintain and deepen COVID-19 vaccine leadership Approved products across various disease areas Expand to new disease areas: autoimmune disease, regenerative medicine, cardiovascular diseases Long-term vision BIONTECH#17Taking mRNA from vision to reality 17 BNT162b2 BONTech COVID-19 V a vial contains 5 doses of ular use, Contains no pre de Emergency Use Auth MEFORE USE. hours after dilution wher 2 25°C (35 to 77°F and time COMIRNATYⓇ COVID-19 mRNA Vaccine First ever approved mRNA therapy¹ Fastest vaccine development in medical history One of the most successful pharmaceutical launches in history² >1 bn individuals vaccinated in 2021 COMIRNATY market share³: USA: -74%; EU: -80% Millions of cases of severe illness or death likely averted 4 Trillions of dollars of global economic impact5 ¹Approved for emergency use/temporary supply or Conditional Marketing Authorization in more than 90 countries worldwide including the U.S. and EU, December 2021 2 Doses shipped in first year after launch; 3 As of mid December 2021; 4 Eric C. Schneider et al., The U.S. COVID-19 Vaccination Program at One Year: How Many Deaths and Hospitalizations Were Averted? (Commonwealth Fund, December 2021); European Centre for Disease Prevention and Control; 5Statista Pfizer BIONTECH#182022: Success Through Further Development of the COVID-19 Vaccine 18 2022: Strong market position >3.6 bn doses shipped to 180 countries and regions since product launch¹ • Order book 20221: -2.5 bn doses As of beginning of July 2022 Distribution of COVID-10 vaccine in collaboration with Pfizer Expansion of global market position ✓Pediatric label expansion for different age groups Evaluation and approval of booster ✓Label expansion to additional at-risk groups ✓ Future pandemic preparedness Monitoring of emerging variants Rapid data-guided vaccine adaptation ● ● ✓ Development of variant-adapted and next- generation vaccines. • Plan to launch Omicron-adapted vaccine in fall 2022 ● Multipronged next-generation vaccine strategy designing and testing multiple constructs. BIONTECH#19Infectious Diseases: Important Area of Growth 19 Ⓡ Addressing a high medical need Tackling global health problems (malaria, tuberculosis, and HIV) Combating diseases for which there is not yet a prophylactic vaccine or therapy Al: Artificial intelligence; Riibologics: *mRNA encoded cancer-targeting antibodies and cytokines Ⓡ Applying new technologies, including mRNA vaccines Wide range of innovative technologies ● trans-amplifying mRNA Ribologicals synthetic anti-bacterial agents (synthetic lysins) Al methods to accelerate the development of new vaccines and therapies ● BIONTECH#20Infectious Disease Pipeline: 4 mRNA Vaccine Trial Starts Expected in 2022 20 5 mRNA vaccines partnered w/Pfizer 10+ other infectious disease programs Indication COVID-191 COVID-191 Influenza (mod mRNA)¹ Influenza (sa mRNA)¹ Shingles¹ HSV 2² Tuberculosis ³ Malaria HIV 3 Additional mRNA vaccine programs ² Precision antibacterials Product candidate Pre-clinical Phase 1 BNT 162b2 BNT162b5 BNT 161 Un-named program Un-named program BNT 163 BNT164 BNT165 Un-named program Un-named programs Un-named programs Phase 2 Commercial Milestones 2022 Multiple updates Phase 2 started in July 2022 Data updated in July 2022 Start Phase 1: 2H 2022 Start Phase 1: 2H 2022 Start Phase 1: 2H 2022 / early 2023 Start Phase 1: 2H 2022 / early 2023 ¹Collaboration with Pfizer; 2University of Pennsylvania collaboration; ³Collaboration with Bill & Melinda Gates Foundation. BioNTech holds worldwide distribution rights except developing countries where BMG holds distribution rights. BIONTECH#21Oncology: New Precision Therapies with Scaling Potential Our innovative approach 21 Development of precise immuno- oncology therapies Individualized therapeutic approaches Scale of platforms across tumor indications Combination of different immuno- oncology mode of action Overcoming therapeutic limitatons in the treatment of solid tumors Inter- Individual Variability A future model for immuno-oncology Cinical Samples sõìÎ{ Tailored on-demand Immunotherapies Patient Sample Profiling Diagnostics & Bioinformatics Big Data, Deep Data, Artificial Intelligence, Machine Learning BIONTECH H Off-the-shelf drugs Drug Classes LATNL do mRNA Therapeutics Engineered Cell Therapies Antibodies Small Molecule Immunomodulators BIONTECH#22Oncology: Potential To Tackle Multiple Diseases With Different Therapeutic Modalities Next Generation Immunomodulators iNeST / Fix Vac Induces multi-specificity, multi-valency, high tumor-antigen specific cell responses with unprecedented potency • mRNA Cancer Vaccines 22 4 Phase 2 randomized trials (2 iNeST and 2 FixVac) Cell Therapies Next Gen CAR-T Cell / Neoantigen-based T Cell / Personalized TCR-T Cell Therapy ● 2 Phase 1 FIH trials started in Feb. and Apr. 2021 Targeted Cancer Antibodies ● Antibodies ● Novel cancer cell surface targets for underserved high medical need cancers CA 19-9 antibody in 1L pancreatic cancer in Phase 1/2 trial + Small Molecule Immunomodulators TLR-7 Agonist ● Potently modulates innate immunity Phase 1 trial CAR, Chimeric antigen receptor; TCR, T Cell receptor; FIH, First-in-human; CA 19-9: Cancer antigen 19-9; 1L, first-line; TLR-7, Toll-like receptor 7; CPI, Check-point Inhibitor ● Bispecifics Next-generation checkpoint inhibitors to address a broad range of cancers Phase 1/2 trials of 2 bispecific antibodies 1 Phase 2 randomized trial ● ● • ● Ribocytokines, RiboMabs mRNA encoded cytokines or antibodies with potential for improved properties and half life Potential to amplify vaccines and CPIs ● 2 Phase 1 FIH RiboCytokine trials Ribologicals 2 Phase 1 FIH RiboMab trials Multiple product opportunities with unique combination potential in clinical testing BIONTECH#23Oncology Pipeline: Significant Progress and Expansion in 2022 Drug class Platform mRNA Cell therapies Antibodies SMIM 23 Fix Vac iNeST Adjuvant colorectal cancer Solid tumors Adjuvant pancreatic ductal adenocarcinoma ¹ Intratumoral immunotherapy SAR441000 (BNT131)³ Solid tumors (IL-12sc, IL 15-sushi, GM-CSF, IFNa) BNT141 Multiple solid tumors (CLDN 18.2) BNT142 Multiple solid tumors (CD3×CLDN6) Multiple solid tumors (optimized IL-2) Multiple solid tumors (IL-7, IL-2) Multiple solid tumors (CLDN6) Pancreatic, other cancers (CLDN 18.2) Multiple solid tumors RiboMabs RiboCytokines CAR T cells + CARVac Neoantigen-based T cells TCR engineered T cells Next-gen immune checkpoint modulators Product candidate BNT111 BNT112 BNT113 BNT 1151 BNT 116 Targeted cancer antibodies Toll-like receptor binding Autogene cevumeran (BNT122)² Indication (targets) Advanced and R/R melanoma Prostate cancer HPV 16+ head and neck cancer Ovarian cancer NSCLC 1L melanoma BNT 151 BNT 152, BNT153 BNT211 BNT212 BNT221 (NEO-PTC-01) To be selected GEN1046 (BNT311)4 GEN1042 (BNT312)4 GEN1053 (BNT313)4 BNT321 (MVT-5873) BNT411 All tumors Metastatic NSCLC (PD-L1x4-1BB) Multiple solid tumors (PD-L1x4-1BB) Multiple solid tumors (CD40×4-1BB) Malignant solid tumors (CD27) Pancreatic cancer (sLea) Solid tumors (TLR7) SMIM, small molecule immunomodulators. 1 Investigator-initiated Phase 1 trial; 2 Collaboration with Genentech; 3 Collaboration with Sanofi; 4 Collaboration with Genmab. Pre-clinical Phase 1 Phase 2 Phase 3 TILLIAJI Milestones FPD in July 2022 Data update: 1H 2023 FPD in Jan. 2022 FPD in July 2022 Data update: 2H 2022 Start Phase 1: 2H 2022 BIONTECH#24Oncology Programs in Phase 2 Platform Fix Vac Program BNT111 How Why Off-the-shelf mRNA vaccine 24 R/R Melanoma Encodes 4 tumor- associated antigens U.S. Fast Track Designation and Orphan Drug Designation Potential to improve outcomes in combo with anti-PD1 BNT113 HPV16+ HNSCC Encodes HPV16 oncoproteins Potential for synergistic anti-tumor effect in combination with anti-PD1 iNeST Individualized mRNA immunotherapy BNT122 Autogene cevumeran¹ 1L Melanoma Targets 20 neo-antigens unique to each patient Data update expected 1H 2023 Trial success may unlock 1L use of iNeST as combination therapy with anti-PD (L)1 in anti-PD1- naive advanced cancers BNT122 Autogene cevumeran¹ Adjuvant colorectal cancer Targets 20 neo-antigens unique to each patient Potential to address residual cancer cells that remain focus on recurrence free survival R/R, refractory/relapsed; HPV16+, human papilloma virus type 16 positive; HNSCC, head and neck squamous cell carcinoma; NK cell, natural killer cell; CPI, checkpoint inhibitor 1 Collaboration with Genentech, 2 Collaboration with Genmab. Bispecific Next-generation immunotherapy BNT311² R/R NSCLC Conditional 4-1BB co- stimulation while blocking PD(L)1 axis Enhances T-cell and NK cell function and targets them to tumor lesions BIONTECH#25OUTLOOK 2022 BIONTECH#26Selected 2022 Pipeline Milestones COVID-19 vaccine: Follow on and Next Gen Vaccines 4 Infectious Disease First-In-Human Trial Starts 4 Oncology First-in- Human Trial Starts 26 3 Data Updates Milestones Omicron BA.4/5-adapted bivalent vaccine trial start BNT162b5: Next-generation bivalent vaccine, enhanced SARS-CoV-2 encoding ancestral and BA.2 spike antigen T cell enhancing vaccine trial start Additional next-generation vaccine trial starts, including pan-SARS-CoV-2 vaccine Multiple data updates Shingles vaccine ¹ BNT163 HSV2 vaccine BNT164 tuberculosis vaccine² BNT 165 malaria vaccine BNT141 RiboMab in solid tumors (CLDN18.2) BNT142 RiboMab in solid tumors (CD3×CLDN6) BNT116 FixVac in combo with Cemiplimab in NSCLC BNT313 (GEN1053) in solid tumors³ BNT 161 influenza mRNA vaccine ¹ BNT1224 Phase 2 iNeST in combo with Pembro in frontline melanoma BNT211 Phase 1/2 CAR-T/CLDN6+ in multiple solid tumors HSV 2, Herpes simplex virus type 2; FPD, first patient dosed; CLDN, Claudin; NSCLC, non-small cell lung cancer 1 Partnered with Pfizer; 2 Collaboration with BMGF; 3 Collaboration with Genmab 4 Partnered with Genentech Anticipated Timing August 2022 Phase 2: FPD July 2022 2H 2022 2H 2022 2H 2022 2H 2022 2H 2022 2H 2022 / early 2023 2H 2022 / early 2023 FPD in Jan. 2022 FPD in July 2022 FPD in July 2022 2H 2022 July 2022 now in 1H 2023 2H 2022 BIONTECH#272022 Strategic Priorities. 27 Continue COVID-19 Vaccine Leadership Care • Label & geographic expansion. Variant-adapted and next- generation vaccines • Innovations for pandemic ● preparedness Execute in Oncology FIH, first-in-human;; Al, artificial intelligence Prepare for registrational trials Additional data for CAR-T cell therapy against solid tumors ● Expand in Infectious Disease Initiate 4 FIH vaccine trials: 10+ additional mRNA vaccine programs Precision antibacterials ● Advance into New Therapeutic Areas Autoimmune disease Regenerative medicine Cardiovascular disease Invest in Foundation to Enable Accelerated Innovation and Expansion Digital & Al Capabilities | Technologies | Development Team | Manufacturing | Global Footprint BIONTECH#28BIONTECH An der Goldgrube 12 55131 Mainz Germany T: +49 6131 908-0 M: [email protected] © Copyright BioNTech SE 2021. All Rights Reserved. January 20, 2021